Buy, Sell or Hold: Sanofi-Aventis (SNY-N) — Stock Predictions at Stockchase

Home Daily Stock Opinions and Ratings Sanofi-Aventis (SNY-N)

NYSE:SNY

48.08

0.35 (0.72%) 1d

This Week’s Stock Picks & BNN Top Picks Summary: META-Q, BDGI-T and 20 Stock and 4 ETF Top Picks (Nov 29-Dec 05)Top Covid-19 Vaccine Stocks to Bet on the Immunization Race (Updated)COVID-19 Stocks to Save Your RRSP + Forecasts and Facts (Updated)

Investor Insights

This summary was created by AI, based on 2 opinions in the last 12 months.

Sanofi-Aventis (SNY-N) is a French pharmaceutical company with a diverse portfolio of products including treatments for MS, myeloma, and dermatitis. The company is trading at 25x earnings, under 2x book value, and is actively reducing long-term debt while also buying back shares. Analysts recommend setting a stop-loss at $42 with an upside potential of 18% to $58. The stock recently touched the bottom of its range but is now breaking out, indicating a possible trade in a higher new range. Overall, the company's strong financials and potential for growth make it an attractive investment.

Consensus

positive

Valuation

Fair Value

Similar

Pfizer Inc, PFE-N

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly

This french pharma company, developer of treatments for MS, myeloma and dermatitis (among many other products) is a TOP PICK. It trades at 25x earnings, under 2x book value and supports a 27% ROE. Cash reserves are being prudently used to reduce long term debt and the company is also buying back shares. We recommend setting a stop-loss at $42, looking to achieve $58 -- upside potential of 18%. Yield 4.2%

(Analysts’ price target is $57.50)

Pharma & Healthcare

RISKY

Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

SNY touched the bottom of its range in October 2023 on weak earnings and news that it would spin-off its consumer healthcare operations. The stock looks to be breaking out and while very hard to predict we think it is possible it trades in a higher new range. The drop last year was likely a one-off driven by the spin-off news, and barring a significant news item as such or consistently weak earnings, we would be surprised if it got back to the low-end of its range.
Unlock Premium - Try 5i Free

Pharma & Healthcare

WEAK BUY

Defensive and probably won't hurt you. Has low, steady growth with reasonable dividend growth. They are developing a Covid vaccine. It's as good as other drug companies, though slightly cheaper.

Pharma & Healthcare

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick May 26/22, Down 12%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with SNY has triggered its stop at $49. To remain disciplined, we recommend covering the position at this time. This will result in a net investment loss of 5.3%, when combined with previous buy recommendations.

Pharma & Healthcare

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly With FDA approval to expand use of one of its key anti-inflammatory treatments, we again reiterate, SNY as a TOP PICK. The drug is expected to generate annual sales over $13 billion -- 30% more than previously estimated. The company is seeking further approval for use with COPD patients. It pays an annual dividend backed by a payout ratio under 45% of cash flow. We continue to recommend a stop loss at $49, looking towards an initial target of $71 -- potential 27% upside. Yield 3.14% (Analysts’ price target is $70.75)

Pharma & Healthcare

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O’Reilly We again reiterate, SNY (a top French biotech that produces a wide range of vaccines and pharmaceuticals by prescription), as a TOP PICK. It has announced a collaboration with a smaller developer that could be a game changer for its cancer related products. It recently beat recent analyst earnings expectations by 16% and is managing a 24% ROE. It pays an annual dividend backed by a payout ratio under 50% of cash flow. We recommend keeping the stop tight at $49, looking towards an initial target of $63 -- potential 22% upside. Yield 3.7% (Analysts’ price target is $63.00)

Pharma & Healthcare

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Dec 28/21, Up 5.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with SNY is progressing well. We now recommend trailing up the stop (from $47) to $49.

Pharma & Healthcare

DON'T BUY

Pays good dividend and has solid balance sheet. Has been unable to produce Covid-19 vaccine. Wouldn't recommend buying.

Pharma & Healthcare

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly SNY is a French biotech that produces a wide range of vaccines and pharmaceuticals by prescription and is reiterated as a TOP PICK. Its new management team has improved its internal drug pipeline and expanded margins and EPS since joining in 2018. It beat recent analyst earnings expectations by 16% and is managing a 25% ROE. It pays an annual dividend that should be announced in the next couple of months with a yield backed by a payout ratio under 50% of cash flow. We recommend trailing up the stop (from $45) to $47, looking towards an initial target of $64.50 -- 27% upside. Yield 3.85% (Analysts’ price target is $64.12)

Pharma & Healthcare

BUY

Given the size of the business, the debt is extremely manageable. Steady eddy dividend grower by mid-high single digits over time. Doesn't depend on one large drug, lots in the pipeline. When things get frothy, will underperform, but when things turn the other way it will do well. A pretty good bet.

Pharma & Healthcare

WATCH

Trades around 15x PE and pays around a 4% dividend. Their future is in the vaccine side, but flu rather than Covid. Interesting company and worth studying further.

Pharma & Healthcare

PAST TOP PICK

(A Top Pick Mar 12/20, Up 36%) A world-class vaccine-maker. He likes pharmas going forward. SNY is facing a patent cliff, but have bought and are developing new drugs to solve this. He's happy to own and buy this.

Pharma & Healthcare

DON'T BUY

Done well recently as part of the vaccine trade. No real revenue growth over the last 5 years. Stagnant profits. Decent dividend. See his Top Picks today for exposure to healthcare.

Pharma & Healthcare

DON'T BUY

They are waiting for approval for their vaccine against COVID in Japan. They are pretty much an oncology firm. You have to compare against other companies in the sector. This one does fine with a PE of 8.8 times and the payout ratio is quite low. The dividends and cash flow are not growing, however. They have to come out with a blockbuster product. See his top picks today for a preferable.

Pharma & Healthcare

BUY

A very good company. Pays a 3.5% dividend yield. Historically, he expected more from their Covid vaccine, though.

Pharma & Healthcare

Showing 1 to 15 of 45 entries

Sanofi-Aventis(SNY-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 1

Stockchase rating for Sanofi-Aventis is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Sanofi-Aventis(SNY-N) Frequently Asked Questions

What is Sanofi-Aventis stock symbol?

Sanofi-Aventis is a American stock, trading under the symbol SNY-N on the New York Stock Exchange (SNY). It is usually referred to as NYSE:SNY or SNY-N

Is Sanofi-Aventis a buy or a sell?

In the last year, 1 stock analyst published opinions about SNY-N. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Sanofi-Aventis.

Is Sanofi-Aventis a good investment or a top pick?

Sanofi-Aventis was recommended as a Top Pick by on . Read the latest stock experts ratings for Sanofi-Aventis.

Why is Sanofi-Aventis stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Sanofi-Aventis worth watching?

1 stock analyst on Stockchase covered Sanofi-Aventis In the last year. It is a trending stock that is worth watching.

What is Sanofi-Aventis stock price?

On 2024-12-10, Sanofi-Aventis (SNY-N) stock closed at a price of $48.08.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Trending stocks today

Sanofi-Aventis (SNY-N)

NYSE:SNY

This is a Panic-proof Portfolio opinion which is available only for Premium members

Sanofi-Aventis(SNY-N)

Sanofi-Aventis(SNY-N)

Sanofi-Aventis(SNY-N)

This is a Panic-proof Portfolio opinion which is available only for Premium members

Sanofi-Aventis(SNY-N)

This is a Panic-proof Portfolio opinion which is available only for Premium members

Sanofi-Aventis(SNY-N)

This is a Panic-proof Portfolio opinion which is available only for Premium members

Sanofi-Aventis(SNY-N)

This is a Panic-proof Portfolio opinion which is available only for Premium members

Sanofi-Aventis(SNY-N)

Sanofi-Aventis(SNY-N)

This is a Panic-proof Portfolio opinion which is available only for Premium members

Sanofi-Aventis(SNY-N)

Sanofi-Aventis(SNY-N)

Sanofi-Aventis(SNY-N)

Sanofi-Aventis(SNY-N)

Sanofi-Aventis(SNY-N)

Sanofi-Aventis(SNY-N)

Sanofi-Aventis(SNY-N)

Sanofi-Aventis(SNY-N) Rating

Sanofi-Aventis(SNY-N) Frequently Asked Questions

What is Sanofi-Aventis stock symbol?

Is Sanofi-Aventis a buy or a sell?

Is Sanofi-Aventis a good investment or a top pick?

Why is Sanofi-Aventis stock dropping?

Is Sanofi-Aventis worth watching?

What is Sanofi-Aventis stock price?

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Lorne Steinberg

The Panic-Proof Portfolio (Stockchase Research)

Larry Berman CFA, CMT, CTA

Teal Linde

Stockchase Insights